AQR Capital Management
AKBA icon

AQR Capital Management’s Akebia Therapeutics AKBA Stock Holding History

AQR Capital Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.49M Buy
1,792,620
+1,145,941
+177% +$1.57M ﹤0.01% 2205
2025
Q4 		$1.04M Buy
646,679
+204,207
+46% +$428K ﹤0.01% 2528
2025
Q3 		$1.21M Buy
442,472
+16,523
+4% +$55K ﹤0.01% 2312
2025
Q2 		$1.55M Buy
425,949
+248,988
+141% +$684K ﹤0.01% 1938
2025
Q1 		$340K Buy
176,961
+20,499
+13% +$41.8K ﹤0.01% 2634
2024
Q4 		$297K Buy
156,462
+15,413
+11% +$26.8K ﹤0.01% 2497
2024
Q3 		$186K Buy
+141,049
New +$188K ﹤0.01% 2587
2022
Q3 		– Sell
-862,168
Closed -$304K – 2177
2022
Q2 		$304K Buy
862,168
+677,703
+367% +$284K ﹤0.01% 1866
2022
Q1 		$132K Buy
184,465
+102,691
+126% +$220K ﹤0.01% 2117
2021
Q4 		$185K Buy
81,774
+9,004
+12% +$24.6K ﹤0.01% 2100
2021
Q3 		$210K Buy
72,770
+58,751
+419% +$168K ﹤0.01% 2139
2021
Q2 		$53K Sell
14,019
-25,229
-64% -$84.9K ﹤0.01% 2208
2021
Q1 		$133K Sell
39,248
-160,845
-80% -$579K ﹤0.01% 2143
2020
Q4 		$560K Sell
200,093
-167,193
-46% -$488K ﹤0.01% 1738
2020
Q3 		$922K Buy
367,286
+138,227
+60% +$1.21M ﹤0.01% 1448
2020
Q2 		$3.11M Buy
229,059
+11,936
+5% +$123K 0.01% 964
2020
Q1 		$1.65M Sell
217,123
-80,356
-27% -$625K ﹤0.01% 1147
2019
Q4 		$1.88M Buy
297,479
+207,708
+231% +$987K ﹤0.01% 1292
2019
Q3 		$352K Buy
89,771
+78,575
+702% +$337K ﹤0.01% 1870
2019
Q2 		$54K Buy
+11,196
New +$63.7K ﹤0.01% 2050
2018
Q2 		– Sell
-22,622
Closed -$216K – 2314
2018
Q1 		$216K Sell
22,622
-17,209
-43% -$241K ﹤0.01% 2122
2017
Q4 		$592K Sell
39,831
-11,785
-23% -$195K ﹤0.01% 1859
2017
Q3 		$1.01M Buy
+51,616
New +$794K ﹤0.01% 1666

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management's AKBA Position: Q1 2026 in Review

AQR Capital Management increased its Akebia Therapeutics (AKBA) stake by 177% in Q1 2026, buying an estimated $1.57M and bringing the position to 1,792,620 shares worth $2.49M. The position accounts for ﹤0.01% of the portfolio, ranked #2205.

AQR Capital Management first reported a position in AKBA in Q3 2017 and has held it in 23 quarters since. The position peaked at $3.11M in Q2 2020. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • AQR Capital Management held 1,792,620 shares of Akebia Therapeutics worth $2.49M as of Q1 2026.
  • AQR Capital Management bought 1,145,941 Akebia Therapeutics shares in Q1 2026, an estimated $1.57M.
  • Akebia Therapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #2205 holding.
  • AQR Capital Management first reported a position in Akebia Therapeutics in Q3 2017 and has held it in 23 quarters since.
  • AQR Capital Management's Akebia Therapeutics position peaked at $3.11M in Q2 2020.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.